Home Pilots GrayMatters Health receives FDA 510(k) for PTSD neuromodulation therapy Pilots GrayMatters Health receives FDA 510(k) for PTSD neuromodulation therapy By - March 27, 2023 40 0 Facebook Twitter Pinterest WhatsApp The company’s product, Prism, uses neurofeedback to help PTSD patients learn to control their emotional response. RELATED ARTICLESMORE FROM AUTHOR Pilots Medtronic issues voluntary recall of MiniMed insulin pumps Pilots Hybrid primary care company Rezilient Health scores $10M Pilots Empathy Health Technologies raises $2.8M for Sober Sidekick app LEAVE A REPLY Cancel reply Please enter your comment! Please enter your name here You have entered an incorrect email address! Please enter your email address here Save my name, email, and website in this browser for the next time I comment. FOLLOW ME0FansLike0FollowersFollow0SubscribersSubscribe POPULAR ARTICLES TeleRare Health launches to offer virtual care to rare disease patients Pilots - May 1, 2024 0 Predictions for digital health funding in 2024 Pilots - December 19, 2023 0 23andMe receives FDA clearance for genetic test for prostate cancer marker Pilots - January 10, 2022 0 SamaCare garners $17M for its specialty medication workflow platform Pilots - May 30, 2024 0 Lokavant raises $21M for clinical trial data platform Pilots - December 7, 2022 0 POPULAR CATEGORIESPilots2166Applications682Testing237Collaborations15GitHub3